Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 36

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 36
---
 integrity, and availability of information),
which may compromise our system infrastructure or lead to data leakage. We have technology security initiatives and disaster recovery
plans in place to mitigate our risk to these vulnerabilities, but these measures may not be adequately designed or implemented to ensure
that our operations are not disrupted or that data security breaches do not occur. To the extent that any disruption or security breach
were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and reputational damage.

Hackers and data thieves are increasingly sophisticated
and operate large-scale and complex automated attacks which may remain undetected until after they occur. We cannot assure you that our
data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our
systems, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition.
For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our
programs, and the development of our diagnostic tests and therapeutic product candidates could be delayed. In addition, the loss of clinical
trial data for our diagnostic tests and therapeutic product candidates could result in delays in our marketing approval efforts and significantly
increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems
or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention
of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and
personal information), which could result in financial, legal, business, and reputational harm to us. Like all businesses we may be increasingly
subject to ransomware or other malware that could significantly disrupt our business operations or disable or interfere with necessary
access to essential data or processes. Numerous recent attacks of this nature have also involved exfiltration and disclosure of sensitive
or confidential personal or proprietary information, or intellectual property, when victim companies have not paid the cyber criminals
substantial ransom payments. For example, any such event that leads to unauthorized access, use, disclosure, unavailability, or compromised
integrity of personal or other sensitive or essential information, including personal information regarding our clinical trial subjects
or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law
equivalents, subject us to mandatory corrective